[L-MTP-PE--a potential antineoplastic agent].
Muramyl tripeptide phosphatidylethanolamine (MTP-PE), a synthetic lipophilic analogue of muramyl dipeptide, stimulates monocytes/macrophages to kill a variety of tumor cells in vitro and in vivo. Encapsulation of MTP-PE into multilamellar liposomes (L-MTP-PE) was specifically designed for in vivo targeting to macrophages by i.v. infusion and is the only form of the drug currently available for clinical trials (CGP 19835A Lipid). L-MTP-PE is presently undergoing clinical trials in patients with recurrent osteosarcoma and melanoma. L-MTP-PE combined with other anticancer agents may thus improve long-term cure rates of patients with this diseases.
Dzierzbicka
K
K
Katedra Chemii Organicznej, Politechniki Gdańskiej w Gdańsku.
Gozdowska
M
M
Kołodziejczyk
A M
AM
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007262:Infusions, Intravenous; D008264:Macrophages / Q000187:drug effects; D008545:Melanoma / Q000188:drug therapy*; D012516:Osteosarcoma / Q000188:drug therapy*; D010714:Phosphatidylethanolamines / Q000494:pharmacology* / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D010714:Phosphatidylethanolamines; C037144:mifamurtide; D000119:Acetylmuramyl-Alanyl-Isoglutamine
L-MTP-PE--potencjalny lek przeciwnowotworowy.